Small cell lung carcinoma
Information
- Disease name
- Small cell lung carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03532880 | Active, not recruiting | Phase 1 | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | July 12, 2018 | June 2024 |
| NCT02041845 | Active, not recruiting | N/A | Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer | July 8, 2014 | December 31, 2033 |
| NCT04665856 | Active, not recruiting | Phase 3 | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | December 22, 2020 | April 15, 2025 |
| NCT03850067 | Active, not recruiting | Phase 1 | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | March 12, 2019 | June 26, 2024 |
| NCT02487095 | Active, not recruiting | Phase 1/Phase 2 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | July 30, 2015 | October 30, 2025 |
| NCT03509012 | Active, not recruiting | Phase 1 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors | May 2, 2018 | December 31, 2024 |
| NCT05450965 | Active, not recruiting | Phase 2 | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | July 19, 2022 | December 2027 |
| NCT05224141 | Active, not recruiting | Phase 3 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) | March 24, 2022 | June 7, 2027 |
| NCT04938817 | Active, not recruiting | Phase 1/Phase 2 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | August 19, 2021 | November 2, 2026 |
| NCT04358237 | Active, not recruiting | Phase 1/Phase 2 | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. | September 21, 2020 | February 20, 2024 |
| NCT03568097 | Active, not recruiting | Phase 2 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer | September 16, 2018 | April 2024 |
| NCT04902872 | Active, not recruiting | Phase 1/Phase 2 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | May 3, 2021 | September 2024 |
| NCT01317953 | Available | Oral Green Tea Extract for Small Cell Lung Cancer | |||
| NCT04507919 | Available | Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | |||
| NCT04672928 | Completed | Phase 1 | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | December 14, 2020 | January 31, 2023 |
| NCT02394548 | Completed | N/A | Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer | June 2015 | March 2021 |
| NCT02397733 | Completed | N/A | Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL) | September 2014 | December 2020 |
| NCT02658214 | Completed | Phase 1 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | April 28, 2016 | November 14, 2019 |
| NCT02763579 | Completed | Phase 3 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | June 7, 2016 | July 7, 2022 |
| NCT02874664 | Completed | Phase 1 | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | September 2016 | September 12, 2018 |
| NCT03092934 | Completed | Phase 1/Phase 2 | A Study of AK-01 (LY3295668) in Solid Tumors | May 29, 2017 | April 20, 2020 |
| NCT04028050 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | August 12, 2019 | July 13, 2023 |
| NCT03232593 | Completed | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | November 29, 2017 | August 12, 2022 | |
| NCT00423254 | Completed | Phase 1 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | February 2007 | November 2009 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT00445198 | Completed | Phase 1/Phase 2 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | April 2007 | December 2010 |
| NCT00759824 | Completed | Phase 2 | A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide | September 2008 | June 2014 |
| NCT00926640 | Completed | Phase 1 | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | July 1, 2009 | April 20, 2018 |
| NCT00927875 | Completed | Phase 1 | A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer | February 2010 | September 2012 |
| NCT01222936 | Completed | Phase 2 | LBH Phase II in Small Cell Lung Cancer (SCLC) | May 2008 | August 2010 |
| NCT01286987 | Completed | Phase 1 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | January 3, 2011 | January 30, 2017 |
| NCT01357395 | Completed | Phase 2 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | May 2011 | May 28, 2012 |
| NCT00143455 | Completed | Phase 3 | Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer | June 2002 | December 2008 |
| NCT01450761 | Completed | Phase 3 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | December 13, 2011 | May 17, 2017 |
| NCT01540045 | Completed | Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer | December 2010 | May 2012 | |
| NCT01553916 | Completed | Phase 1/Phase 2 | Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain | April 26, 2012 | June 5, 2017 |
| NCT01941316 | Completed | Phase 1/Phase 2 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | November 2013 | July 1, 2019 |
| NCT06419179 | Not yet recruiting | Phase 2 | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) | September 2024 | December 2026 |
| NCT05703997 | Not yet recruiting | Phase 2 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction | January 2023 | January 2029 |
| NCT06236997 | Not yet recruiting | Phase 2 | Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | February 10, 2024 | December 31, 2027 |
| NCT05683977 | Recruiting | A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. | November 14, 2022 | April 16, 2027 | |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT03319940 | Recruiting | Phase 1 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | December 26, 2017 | October 18, 2025 |
| NCT03735095 | Recruiting | Phase 1/Phase 2 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | February 12, 2020 | February 12, 2030 |
| NCT04199741 | Recruiting | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | December 11, 2019 | June 11, 2026 | |
| NCT04996771 | Recruiting | Phase 1/Phase 2 | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | November 9, 2021 | December 31, 2024 |
| NCT05049863 | Recruiting | Phase 1/Phase 2 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | February 27, 2023 | October 31, 2025 |
| NCT05265429 | Recruiting | Biology of Young Lung Cancer Study: The YOUNG LUNG Study | January 1, 2023 | August 1, 2027 | |
| NCT05329623 | Recruiting | Phase 1 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | May 3, 2022 | June 17, 2024 |
| NCT05419076 | Recruiting | Phase 2 | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | June 10, 2022 | June 10, 2025 |
| NCT05616624 | Recruiting | Phase 1/Phase 2 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | April 5, 2023 | December 31, 2032 |
| NCT05617963 | Recruiting | Phase 2 | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax | March 24, 2023 | March 30, 2029 |
| NCT05620342 | Recruiting | Early Phase 1 | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | June 21, 2023 | February 15, 2027 |
| NCT05882058 | Recruiting | Phase 2 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | September 25, 2023 | July 3, 2025 |
| NCT05945745 | Recruiting | Molecular Analysis and Treatment Options of SCLC | January 1, 2016 | December 31, 2028 | |
| NCT06131840 | Recruiting | Phase 1 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | November 20, 2023 | March 31, 2030 |
| NCT06177925 | Recruiting | Phase 2 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | December 10, 2023 | September 30, 2026 |
| NCT06247163 | Recruiting | PET-guided Radiotherapy for Patients With Small Cell Lung Cancer. | February 22, 2024 | February 22, 2029 | |
| NCT06247605 | Recruiting | Phase 3 | A Phase IIII Study of AL8326 in Small Cell Lung Cancer | October 26, 2023 | July 2029 |
| NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
| NCT01187615 | Terminated | Phase 1 | Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer | August 2010 | June 2012 |
| NCT01574300 | Terminated | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network | November 2010 | March 1, 2019 | |
| NCT04173325 | Terminated | Phase 1 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | January 6, 2020 | May 26, 2022 |
| NCT01573338 | Terminated | Phase 1/Phase 2 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer) | February 25, 2013 | June 23, 2016 |
| NCT02937402 | Terminated | N/A | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer | April 5, 2018 | August 20, 2019 |
| NCT00977561 | Terminated | Phase 2 | A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer | April 2010 | October 2011 |
| NCT00299390 | Terminated | Phase 2 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | April 2006 | April 2007 |
| NCT02161419 | Terminated | Phase 2 | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer | July 30, 2014 | May 25, 2016 |
| NCT01722292 | Terminated | Phase 1/Phase 2 | A Study of LY2940680 in Small Cell Lung Cancer | January 2013 | February 2015 |
| NCT02062632 | Terminated | Phase 2 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | April 14, 2014 | November 6, 2017 |
| NCT03662074 | Terminated | Phase 2 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer | November 7, 2018 | February 3, 2022 |
| NCT05027867 | Terminated | Phase 2 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | December 6, 2021 | August 26, 2022 |
| NCT03963414 | Terminated | Phase 1 | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | September 25, 2020 | December 15, 2021 |
| NCT04901754 | Unknown status | Phase 2 | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer | July 14, 2021 | March 31, 2023 |
| NCT03700359 | Unknown status | Phase 2 | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | March 1, 2019 | November 29, 2021 |
| NCT01441349 | Unknown status | Phase 2 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | August 2011 | December 31, 2022 |
| NCT03512015 | Unknown status | N/A | A Mobile Supportive Care App for Patients With Metastatic Lung Cancer | May 15, 2018 | June 30, 2020 |
| NCT03994744 | Unknown status | Phase 2 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | August 20, 2019 | July 1, 2022 |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT04363255 | Unknown status | Phase 2 | First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC | May 1, 2020 | March 31, 2023 |
| NCT04453930 | Unknown status | Phase 2 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | June 8, 2020 | June 2023 |
| NCT04620837 | Unknown status | Phase 2 | Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | November 1, 2020 | December 31, 2023 |
| NCT01977235 | Unknown status | Phase 2 | Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer | September 2013 | September 2017 |
| NCT05582031 | Withdrawn | Phase 2 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | April 30, 2023 | April 30, 2025 |
| NCT02876081 | Withdrawn | Phase 2 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex | September 1, 2017 | December 2018 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030357
- MeSH unique ID (MeSH (Medical Subject Headings))
- D055752